Vident Advisory LLC Purchases 13,037 Shares of Danaher Corporation $DHR

Key Points

• Vident Advisory LLC increased its stake in Danaher Corporation by 20.7%, holding a total of 76,023 shares valued at approximately $15.6 million after acquiring an additional 13,037 shares.
• Following recent transactions, over 79% of Danaher’s stock is held by institutional investors, indicating strong institutional confidence in the company.
• Wall Street analysts maintain a positive outlook on Danaher, with most rating it as a "buy" and setting an average price target of $247.61.

Vident Advisory LLC increased its holdings in shares of Danaher Corporation (NYSE:DHR - Free Report) by 20.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 76,023 shares of the conglomerate's stock after purchasing an additional 13,037 shares during the quarter. Vident Advisory LLC's holdings in Danaher were worth $15,585,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. FAS Wealth Partners Inc. grew its holdings in Danaher by 20.6% during the 4th quarter. FAS Wealth Partners Inc. now owns 9,597 shares of the conglomerate's stock valued at $2,203,000 after buying an additional 1,639 shares in the last quarter. MGO One Seven LLC lifted its holdings in shares of Danaher by 485.7% in the first quarter. MGO One Seven LLC now owns 25,098 shares of the conglomerate's stock worth $5,145,000 after buying an additional 20,813 shares in the last quarter. Asahi Life Asset Management CO. LTD. bought a new position in shares of Danaher during the first quarter worth $539,000. Horizon Financial Services LLC grew its stake in Danaher by 20,400.0% during the first quarter. Horizon Financial Services LLC now owns 8,200 shares of the conglomerate's stock valued at $1,681,000 after acquiring an additional 8,160 shares in the last quarter. Finally, Texas Capital Bank Wealth Management Services Inc grew its stake in Danaher by 6.1% during the first quarter. Texas Capital Bank Wealth Management Services Inc now owns 34,763 shares of the conglomerate's stock valued at $7,126,000 after acquiring an additional 2,009 shares in the last quarter. Institutional investors own 79.05% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have commented on DHR. Wall Street Zen raised shares of Danaher from a "hold" rating to a "buy" rating in a report on Friday, June 27th. Deutsche Bank Aktiengesellschaft dropped their price target on Danaher from $240.00 to $235.00 in a research note on Thursday, June 5th. Guggenheim reaffirmed a "buy" rating and issued a $250.00 price objective on shares of Danaher in a research note on Wednesday, July 23rd. UBS Group decreased their price objective on Danaher from $240.00 to $225.00 and set a "buy" rating on the stock in a report on Wednesday, July 23rd. Finally, Scotiabank raised shares of Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 target price for the company in a report on Friday, July 11th. Seventeen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Danaher currently has an average rating of "Moderate Buy" and an average target price of $247.61.

Danaher Trading Up 0.4%

NYSE:DHR traded up $0.80 during mid-day trading on Monday, hitting $206.09. 1,979,809 shares of the stock traded hands, compared to its average volume of 3,131,448. The stock has a market capitalization of $147.57 billion, a price-to-earnings ratio of 43.85, a PEG ratio of 2.87 and a beta of 0.75. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $279.90. The firm's 50 day moving average is $201.65 and its two-hundred day moving average is $199.46. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The business had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. During the same quarter last year, the firm earned $1.72 earnings per share. The firm's quarterly revenue was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, equities research analysts predict that Danaher Corporation will post 7.63 earnings per share for the current year.

Insider Buying and Selling at Danaher

In other news, Director Teri List sold 2,778 shares of the business's stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the sale, the director directly owned 20,751 shares of the company's stock, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 11.20% of the company's stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.